Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum

Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum

Chronic kidney disease (CKD) is a global health problem and an independent risk factor for cardiovascular morbidity and mortality. Despite evidence-based therapies significantly improving cardiovascular mortality outcomes in the general population and those with non-dialysis-dependent CKD, this risk...

Full description

Bibliographic Details
Main Authors: Frances L. Varian, William A. E. Parker, James Fotheringham, Robert F. Storey
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Platelets
Subjects:
acute coronary syndrome (acs)
antiplatelet
cardiovascular disease
chronic kidney disease (ckd)
end stage kidney disease (eskd)
ischaemic heart disease (ihd)
p2y12 inhibitor
renal replacement therapy (rrt)
Online Access:http://dx.doi.org/10.1080/09537104.2022.2154330

Internet

http://dx.doi.org/10.1080/09537104.2022.2154330

Similar Items